NON-HODGKIN LYMPHOMA

This early-stage trial tested a new drug called GEN3017 in people with CD30-positive Hodgkin or non-Hodgkin lymphoma that had returned or stopped responding to other treatments. The goal was to check safety and find the right dose. Only 9 people took part before the study was sto…

This study looked at a new way to prevent severe graft-versus-host disease (GVHD) in children who had a bone marrow transplant for blood cancers. The goal was to see if stopping certain immune-suppressing drugs early could lower the risk of severe GVHD. Only 3 children took part …

This study tested whether the blood pressure drug telmisartan could prevent acute graft-versus-host disease (GVHD) in 32 people with blood cancers receiving a stem cell transplant. GVHD is a serious complication where donor cells attack the patient's body. The trial was stopped e…

This study tested a new treatment called CTX110 for people with B-cell blood cancers that came back or didn't respond to standard therapy. CTX110 uses CRISPR gene editing to create donor immune cells that can attack cancer. The study aimed to find safe doses and check if the trea…

This early-stage study tested an experimental oral drug called AUR105 in 17 adults with advanced solid tumors or lymphomas that had come back after prior treatment. The goal was to check safety, find the right dose, and see how the body processes the drug. The study was terminate…

This early-phase study tested a new drug called AUR103 Calcium in 27 adults with advanced solid tumors, acute myeloid leukemia, myelodysplastic syndromes, or non-Hodgkin lymphoma who had no other treatment options. The goal was to find the best dose and check safety. The study wa…

This early-stage trial tested a new drug called IPH6501 in 23 people with a type of blood cancer (Non-Hodgkin lymphoma) that had returned or stopped responding to other treatments. The main goals were to check the drug's safety and find the best dose. The study was stopped early,…

This early-stage trial tested a two-step radiation treatment for people with non-Hodgkin lymphoma that had come back or stopped responding to standard therapies. The treatment uses a special protein to deliver radiation directly to cancer cells. Only one person enrolled before th…

This study looked at whether a quick, 5-minute daily breathing exercise using a small handheld device, combined with a personalized workout plan, can improve heart health and fitness in people who have finished treatment for Hodgkin or non-Hodgkin lymphoma. The study aimed to rec…